SOUTH SAN FRANCISCO, Calif., April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on April 4, 2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief Medical Officer, on March 27, 2024, vesting over four years with a one-year cliff. Additionally, on March 27, 2024, Ms. Rojkjaer was granted 187,500 stock options to vest upon achievement of certain future performance conditions, subject to her continuous service to the Company on such vesting date.

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel 

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com. 

Investors & Media Contacts
Investors:
Rigel Pharmaceuticals, Inc. 
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.